Poseida Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Poseida Therapeutics

09/08/2023 13:01

* Poseida Therapeutics Inc  PSTX.OQ  reported a quarterly
adjusted
loss of 32 cents​​ per share for the quarter ended in June. The
mean expectation of five analysts for the quarter was for a loss
of 53 cents per share.
    * Revenue rose 641.2% to $20.01 million from a year ago;
analysts
expected $5.08 million. 
    * Poseida Therapeutics Inc's reported EPS for the quarter
was a
loss of 32 cents​.
    * The mean earnings estimate of analysts had risen by
about 3.6%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Poseida Therapeutics Inc shares had risen by 12.5% this
quarter and lost 62.6% so far this year.
    * The company reported a quarterly loss of $27.46 million.
    * Wall Street's median 12-month price target for Poseida
Therapeutics Inc is $12.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 9 at 12:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.53          -0.32          Beat
 Mar. 31 2023      -0.45          -0.45          Met
 Dec. 31 2022      -0.22          -0.39          Missed
 Sep. 30 2022      -0.65          0.92           Beat